ClinicalTrials.gg

Program

Empagliflozin/Linagliptin

Its studies are mostly in Diabetes Mellitus, Type 2, led by Humanis Saglık Anonim Sirketi.

Furthest: phase 1, since Apr 10, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Humanis Saglık Anonim Sirketi20 open or runningphase 1since Apr 10, 2025Apr 10, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 10, 2025First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT06932159 · 40 enrolled · India
  2. Jun 18, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07039890 · 40 enrolled · India

TargetBeta

DPP4 →SLC5A2 →read by rule
“A fixed dose combination of empagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2), and linagliptin, a dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with antihyperglycemic activity”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07039890Diabetes Mellitus, Type 2 · India1CompletedMay 14, 202540
NCT06932159Diabetes Mellitus, Type 2 · India1CompletedMar 7, 202540

How it is read

Names in the registry

  • “Glyxambi film-coated tablets”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.